Duties exempted on 3 drugs

New Delhi

Due to public pressure , octreotide, somatropin and anti-haemophilic factor concentrate (VIII and IX) exempted from custom duties. The government had removed the custom duty on 76 life-saving drugs on February 5. Consequently, out of 76 drugs, customs duty on 15 increased from zero to 35 per cent and on other 61 drugs, the duty rose from five per cent to 10 per cent, respectively. However, after strong protests by patients suffering from haemophilia, the Central Board of Excise and Customs (CBEC) issued a notification on Wednesday restoring the custom duty exemptions on anti- haemophilic factor concentrate (VIII and IX). Octreotide and somatropin were a part of the 61 drugs list where the duty rose from 5 to 10 per cent. Now with the CBEC notification, they will have a duty of five per cent again. Octreotide is used to treat hormonal disorder, besides symptoms of severe diarrhoea and flushing caused by cancer. Somatropin is used to treat growth failure in children and adults, who lack natural growth hormone. It is also used to treat chronic kidney failure. Anti-haemophilic factor concentrate (VIII and IX) is used to treat heamophilia, which is a genetic bleeding disorder involving a lack of functional clotting

  • Related Posts

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices